Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 11/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | CPS1 | P31327 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331985 | 0.99 | HPGD (0.53) | ALDH1A1HPGDMTORGRIN2BPIK3CA | |
| SCHEMBL10332046 | 0.96 | GRIN2B (0.51) | ALDH1A1HPGDMTORGRIN2BPIK3CA | |
| SCHEMBL10331348 | 0.85 | YEATS4 (0.53) | ALDH1A1HPGDMTORPIK3CACPS1 | |
| SCHEMBL10331952 | 0.85 | HPGD (0.53) | ALDH1A1HPGDMTORGRIN2BPIK3CA | |
| SCHEMBL10331353 | 0.83 | YEATS4 (0.54) | ALDH1A1HPGDMTORPIK3CACPS1 | |
| SCHEMBL10331358 | 0.81 | YEATS4 (0.51) | ALDH1A1HPGDMTORPIK3CACPS1 | |
| SCHEMBL10331956 | 0.80 | MEN1 (0.49) | GRIN2B | |
| SCHEMBL10331954 | 0.79 | HPGD (0.61) | ALDH1A1HPGDGRIN2BHRH3 | |
| SCHEMBL10331961 | 0.76 | ALDH1A1 (0.57) | ALDH1A1HPGDGRIN2BGRIN1 | |
| SCHEMBL764280 | 0.76 | ABL1 (0.53) | ALDH1A1HPGDCPS1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | NR3C1, NFRKB, RELA | ALDH1A1 4091/4885HPGD 3552/4885MTOR 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.